A Two-Stage Regression Model for Epidemiological Studies With Multivariate Disease Classification Data
用于多维疾病分类流行病学研究的两阶段回归模型AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确采用多类别 logistic 回归建模疾病类别,依据是离散响应模型而非行为选择解释。
用于多维疾病分类流行病学研究的两阶段回归模型AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Polytomous logistic regression is commonly used to analyze epidemiological data with disease subtype information. In this approach effects of exposures on different disease subtypes are studied through separate exposure odds ratios comparing different case groups to the common control group. This article considers the situation where disease subtypes can be defined using multiple characteristics of a disease. For efficient analysis of such data, a two-stage modeling approach is proposed. At the first stage, a standard polytomous logistic regression model is considered for all possible distinct disease subtypes that can be defined by the cross-classification of the different disease characteristics. At the second stage, the exposure odds ratio parameters for the first-stage disease subtypes are further modeled in terms of the defining characteristics of the subtypes. When the total number of first-stage disease subtypes is small, standard maximum likelihood methods can be used for inference in the proposed model. For dealing with a large number of disease subtypes, a novel semiparametric pseudo-conditional-likelihood approach is proposed that does not require any model assumption about the baseline probabilities for the different disease subtypes. This article develops the asymptotic theory for the estimator and studies its small-sample properties using simulation experiments. The proposed method is applied to study the effect of fiber on the risk of various forms of colorectal adenoma using data available from a large screening study, the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.